No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
New Indication Alert: BMS’ Opdivo® (Nivolumab) Combo Approved in Europe for NSCLC
On 16 May 2025, Bristol Myers Squibb announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo® (nivolumab) and chemotherapy followed by…